FDA Approves First Treatment For MCT8 Deficiency

TL;DR

For listenersOffer from Amazon

Turn your wind-down time into listening time

• Thousands of audiobooks, podcasts and originals
• Listen on your phone, tablet or Echo — also offline
• Cancel anytime

Try Audible free →Free trial for new members

As an affiliate, we earn on qualifying purchases.Hide

The FDA approved Emcitate (tiratricol) to treat peripheral thyrotoxicosis in people with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome. The agency says the drug lowered elevated blood thyroid hormone levels in two studies; it is not described as reversing the neurological effects of the disorder.

The U.S. Food and Drug Administration on September 28, 2026, approved Emcitate (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis in people with MCT8 deficiency, a rare genetic disorder also called Allan-Herndon-Dudley syndrome. The FDA described it as the first treatment it has approved for symptoms of the condition; its stated treatment target is excess thyroid hormone in the blood.

The FDA said Emcitate’s effectiveness was evaluated in two clinical studies involving patients from infancy through adulthood. One was an international, multicenter, randomized, placebo-controlled trial, listed as NCT05579327; the other was a longer-term, open-label study. According to the agency, patients treated with Emcitate had reductions in elevated blood thyroid hormone levels across the studies.

The FDA also reported improvements in cardiovascular and metabolic symptoms affected by thyroid levels, including systolic blood pressure and heart rate. The release does not give the size of these changes, the number of participants, or detailed results by age group. The findings reported by the agency concern hormone levels and symptoms; the announcement does not say that the drug restores thyroid hormone delivery to the brain or reverses neurological disabilities associated with the disorder.

Emcitate is taken once daily as a liquid suspension, by mouth or through a feeding tube. The FDA said this option is intended to accommodate patients who have difficulty swallowing. Reported common side effects were diarrhea, vomiting, rash and excessive sweating. The agency cautioned that patients using another thyroid medication should speak with their health care provider before starting Emcitate, because the two medicines should not be used together.

A Treatment for Excess Blood Hormone

The approval creates an FDA-authorized treatment option for a specific and serious consequence of MCT8 deficiency: excess thyroid hormone circulating in the blood. Before this decision, FDA Deputy Director Marina Zemskova said, patients and families had no FDA-approved treatment option. That distinction matters to families and clinicians facing a condition with substantial care needs, while keeping the scope of the approval clear: Emcitate is approved to treat peripheral thyrotoxicosis, not the full range of effects attributed to the disorder.

The drug’s liquid formulation and feeding-tube administration may be relevant for patients with swallowing difficulties, which the FDA lists among the challenges experienced by some people with MCT8 deficiency. Its reported effect on hormone levels and certain cardiovascular and metabolic measures gives clinicians an approved approach to address those aspects of the condition. How much benefit individual patients experience, and whether effects differ across ages or levels of disease severity, is not established in the announcement.

Why MCT8 Disrupts Hormone Delivery

MCT8 deficiency results from a faulty gene that provides instructions for making the MCT8 transporter, a protein involved in carrying thyroid hormone into the brain. The FDA says that without a functioning transporter, the brain receives too little thyroid hormone while excess hormone builds up in the bloodstream. The condition primarily affects males and is also known as Allan-Herndon-Dudley syndrome.

The FDA described possible effects including difficulty sitting or walking independently, absent or limited speech, intellectual disability, feeding difficulties, and chronic strain on the heart and metabolism. These are effects reported in the agency’s description of the disorder, not outcomes that its release says Emcitate resolves. FDA officials said tiratricol can enter cells without relying on the faulty transporter, offering a way to lower elevated blood hormone levels.

Before approval, Emcitate received Orphan Drug, Rare Pediatric Disease, Fast Track and Breakthrough Therapy designations, as well as Priority Review, according to the FDA. The approval was granted to Egetis Therapeutics US Inc. Those designations and review status describe the regulatory process; they do not by themselves establish the treatment’s degree of benefit.

“This drug sidesteps that problem, as its active ingredient, tiratricol, can enter cells on its own without relying on the broken transporter, leading to a decrease in the elevated blood thyroid hormone levels.”

— Hylton V. Joffe, director of the FDA’s Office of Cardiology, Hematology, Endocrinology, and Nephrology

Questions Beyond Hormone Reduction

The FDA’s announcement does not provide the participant count, numerical treatment effects, study duration or detailed safety rates. It also does not report whether observed effects differed between infants, children and adults, or how long benefits persisted in the longer-term study. The release therefore supports the agency’s stated findings of hormone reductions and improvements in certain cardiovascular and metabolic measures, but it does not allow readers to assess the magnitude of those changes from the information provided.

It is also unclear from the announcement whether Emcitate affects the disorder’s neurological features, such as movement, speech or intellectual disability. The FDA’s stated indication is treatment of peripheral thyrotoxicosis; it does not describe the medicine as a cure or as a treatment that repairs the faulty transporter. Further information about use in individual patients and longer-term outcomes will need to come from prescribing information, study results and clinical follow-up.

Use and Follow-Up After Approval

Emcitate is now FDA-approved for the stated indication, and Egetis Therapeutics US Inc. is the company named in the agency’s release as the approval holder. Patients and caregivers considering treatment should discuss it with a health care professional, especially if the patient is already taking another thyroid medication; the FDA says those medicines should not be used together.

The agency’s release does not specify a commercial availability date, price, recommended dose schedule beyond once-daily administration, or additional follow-up milestones. Clinicians and families will need to consult the product’s prescribing information for approved-use details. Further published data could clarify the size and durability of benefits, side effects and outcomes across age groups; those details were not included in the September 28 announcement.

Key Questions

What did the FDA approve?

The FDA approved Emcitate (tiratricol) to treat peripheral thyrotoxicosis, or excess thyroid hormone in the blood, in patients with MCT8 deficiency, also called Allan-Herndon-Dudley syndrome.

Does Emcitate treat all effects of MCT8 deficiency?

The FDA’s stated approval is for peripheral thyrotoxicosis. Its announcement reports reductions in blood thyroid hormone and improvements in certain cardiovascular and metabolic symptoms, but does not say the drug reverses neurological effects or cures the disorder.

How is Emcitate taken?

It is taken once daily as a liquid suspension, either by mouth or through a feeding tube, according to the FDA.

What side effects did the FDA report?

The common side effects listed in the FDA release are diarrhea, vomiting, rash and excessive sweating. The release does not provide detailed rates for these effects.

Can patients take Emcitate with another thyroid medication?

The FDA says Emcitate and another thyroid medication should not be used together. Patients should speak with their health care provider before starting Emcitate if they take another thyroid medicine.

Source: primary